OxiGene, VaxGen deal

OxiGene said VaxGen had about $33 million in cash, which OxiGene will use to strengthen its programs, including lead Zybrestat fosbretabulin. The A4 prodrug phosphatase-activated tumor vascular targeting agent is in the Phase III portion of a Phase II/III trial for anaplastic thyroid cancer (ATC) and in Phase II testing for polypoidal choroidal vasculopathy (PCV). ...